Print Email Facebook Twitter Development of a new test for the global fibrinolytic capacity in whole blood Title Development of a new test for the global fibrinolytic capacity in whole blood Author Rijken, D.C. Hoegee-de Nobel, E. Jie, A.F.H. Atsma, D.E. Schalij, M.J. Nieuwenhuizen, W. TNO Kwaliteit van Leven Publication year 2008 Abstract Background: The development of global tests for the fibrinolytic capacity in blood is hampered by the low base-line fibrinolytic activity in blood, by the involvement of both plasmatic components and blood cells in the fibrinolytic system and by the loss of fibrinolytic activity as a result of the action of plasminogen activator inhibitor-1 (PAI-1). Objective: To develop a new test for the global fibrinolytic capacity (GFC) of whole blood samples. Methods and results: Collection of blood in thrombin increased the subsequent generation of fibrin degradation products. This was ascribed to rapid clot formation and concomitant reduction of in vitro neutralization of tissue-type plasminogen activator (tPA) by PAI-1. On the basis of this observation, the following test was designed: blood samples were collected in thrombin with and without aprotinin and clots were incubated for 3h at 37°C. The GFC was assessed from the difference between the fibrin degradation products in the two sera. The assay was applied to blood samples from patients and healthy subjects. Other hemostasis parameters were determined in plasma samples taken simultaneously. The GFC varied considerably (normal range 0.13-13.6 μg mL-1); physical exercise strongly increased the GFC. Statistically significant correlations were found with tPA activity, PAI-1 activity and fibrinogen level. A mixture of antibodies against tPA and urokinase-type plasminogen activator (uPA) completely inhibited the GFC. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFI) accelerated fibrinolysis 8-fold. Conclusion: The new test represents a global assessment of the main fibrinolytic factors in plasma and potentially those associated with blood cells. © 2007 International Society on Thrombosis and Haemostasis. Subject BiologyBrinolysisGlobal fibrinolytic capacityPlasminogen activator inhibitor-1Thrombin-activatable fibrinolysis inhibitorTissue-type plasminogen activatorantibodyaprotininfibrinfibrin degradation productfibrinogenplasminogen activator inhibitor 1thrombinthrombin activatable fibrinolysis inhibitortissue plasminogen activatorurokinaseadultagedarticleblood analysisblood cellblood clottingblood samplingclinical articlecontrolled studycorrelation analysisexercisefemalefibrinolysisglobal fibrinolytic capacityhemostasishumanin vitro studyischemic heart diseasemaleplasmapriority journalstatistical significancetransluminal coronary angioplastyAprotininExerciseFibrin Fibrinogen Degradation ProductsFibrinogenFibrinolysisHemostasisHumansLaboratory Techniques and ProceduresPlasminogen Activator Inhibitor 1ThrombinTissue Plasminogen Activator To reference this document use: http://resolver.tudelft.nl/uuid:1af0e4bd-aef3-45d4-a188-898f4bf4b135 DOI https://doi.org/10.1111/j.1538-7836.2007.02816.x TNO identifier 240592 ISSN 1538-7933 Source Journal of Thrombosis and Haemostasis, 6 (1), 151-157 Document type article Files To receive the publication files, please send an e-mail request to TNO Library.